Abstract: Objective To retrospectively analyze immunerelated adverse events and risk factors of carrelizumab among cancer patients, and provide reference for its clinical applications. Methods The clinical data of patients treated with carrilizumab was collected from Jiangsu Province Hospital between July 1, 2021 and June 30, 2022. The safety of clinical medication was assessed by analyzing the clinical pathological features and the incidence of immune-related adverse events (irAEs) among patients with carrilizumab administration. The correlations between irAEs and clinical pathological features were explored. Results Oner hundred and eighty-four out of a total of 528 patients (34.85%) experienced irAEs involving dysfunction of 10 organ systems. The most common adverse reactions were observed in the endocrine system and the skin and soft tissue system. No fatal adverse events were observed. Most of the irAEs were G1~G2 grade, including 117 cases (53.67%) of G1 grade, 86 cases (39.45%) of G2 grade, 12 cases (5.50%) of G3 grade and 3 cases (1.37%) of other grades. The risk factors for irAEs of carrelizumab were identified as hepatitis B infection, tumor type, treatment schemes and the courses of treatment with immune checkpoint inhibitors ICIs (P<0.05). Multivariate analysis suggested that significant factors related to irAEs were the treatment schemes and coursed of treatment (P<0.05). In addition, reactive cutaneous capillary endothelial proliferation RCCEP related to incarrellizumab administration was statistically related to the co-administration of antiangiogenic drugs by multivariate analysis (P<0.05). Conclusion The symptoms of irAEs related to carrilizumab administration are moderate despite the high incidence. Early detection and interventions are of great importance for these patients.

Key words: carrelizumab, tumor, immune checkpoint inhibitors, ICIs, immune-related adverse events, irAEs, immunerelated, adverse drug reaction, risk factors